Nanobiotix (NASDAQ:NBTX) Price Target Lowered to $8.00 at Guggenheim

Nanobiotix (NASDAQ:NBTX) had its price objective reduced by equities research analysts at Guggenheim from $12.00 to $8.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price objective points to a potential upside of 144.72% from the stock’s previous close.

Separately, UBS Group upgraded shares of Nanobiotix to a “hold” rating in a research note on Monday, February 17th.

Nanobiotix Trading Down 3.3 %

NBTX stock traded down $0.11 during trading on Friday, reaching $3.27. The stock had a trading volume of 2,032 shares, compared to its average volume of 13,561. Nanobiotix has a one year low of $2.76 and a one year high of $7.51. The company’s 50 day moving average is $3.60 and its two-hundred day moving average is $3.81.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Millennium Management LLC purchased a new stake in Nanobiotix during the fourth quarter valued at $39,000. Jane Street Group LLC purchased a new position in Nanobiotix in the 4th quarter worth approximately $73,000. Geode Capital Management LLC bought a new position in shares of Nanobiotix during the fourth quarter worth $29,000. Finally, OLD Mission Capital LLC bought a new position in shares of Nanobiotix during the 4th quarter valued at about $139,000. 38.81% of the stock is owned by hedge funds and other institutional investors.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.